Repeated transcatheter aortic valve implantation for the treatment of a degenerated transcatheter aortic valve implantation valve (valve-in-valve technique): a case report

Vassileios Voudris, Ioannis Iakovou, Ilias Kosmas *, and Eftychia Sbarouni

Division of Interventional Cardiology, Onassis Cardiac Surgery Center, 356 Syngrou av, 176 74 Athens, Greece

Received 27 February 2020; first decision 25 March 2020; accepted 13 July 2020; online publish-ahead-of-print 23 October 2020

Background
Valve-in-valve transcatheter aortic valve implantation (TAVI) has emerged as a competent alternative for the treatment of degenerated bioprosthetic valves after surgical aortic valve replacement, or during TAVI procedure as a bailout option. Herein, we report a rare case of a self-expandable Medtronic Evolut R valve into a failing Medtronic CoreValve, with the use of modern pre-TAVI imaging screening, suggesting the proper procedural design steps for so complicated implantations.

Case summary
A frail 78-year-old woman with a degenerated Medtronic Core Valve 26 mm bioprosthesis, implanted in 2011 due to severe aortic stenosis, was referred to our hospital due to worsening dyspnoea New York Heart Association III. The screening echocardiography documented severe aortic stenosis, while the classical risk scores were in favour of repeated TAVI (EuroSCORE II 5.67%). Computed tomography measurements and three-dimensional (3D) printing model were of great help for the proper valve selection (Medtronic Evolut R 26 mm), while the use of cerebral protection device (Claret Sentinel) was considered as a necessary part of the procedure. The simultaneous use of fluoroscopy and transoesophageal echocardiogram led to optimal haemodynamic result, confirmed by the discharge echocardiogram, with a significant clinical improvement during the first month follow-up.

Discussion
The main periprocedural concerns remain valve malpositioning, coronary artery obstruction, and high remaining transvalvular gradients. The multimodality pre-TAVI imaging screening may be helpful for precise procedural design. Despite the limited use of 3D models, it is necessary to adopt such tissue-mimicking phantoms to increase the possibility of optimal procedural result.

Keywords
Degenerated bioprosthetic valve • Valve-in-valve implantation • 3D printing modelling • Cerebral protection device • Case report

*Corresponding author. Tel: + 306942204650, Email: ekosmat@gmail.com
Handling Editor: Julien Adjed
Peer-reviewers: Chiara De Biase and Romain Didier
Compliance Editor: Mark Philip Cassar
Supplementary Material Editor: Deepti Ranganathan
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Learning points

- The valve-in-valve implantation requires accurate anatomical measurements pre-operatively.
- The multimodality pre-transcatheter aortic valve implantation imaging screening with computed tomography, transoesophageal echocardiogram, and three-dimensional (3D) printing modelling may be of great help to choose the proper treatment option.
- The use of 3D models needs to be widely expanded in the field of Interventional Cardiology for the precise design of valvular heart diseases treatment.

Introduction

Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) has emerged as an alternative strategy for the treatment of degenerated bioprosthesis valves after surgical aortic valve replacement (SAVR) or during TAVI procedures as a bailout option. While the TAVI experience has already exceeded a 10-year period and numerous ViV procedures have been reported, only little is known about the long-term durability of these prostheses. On the other hand, technical issues are yet to be resolved; the careful use of three-dimensional (3D) printing assessment may contribute to the selection of the proper therapeutic option, while any possible presence of thrombus on the degenerated valve should be systematically ruled out.

Herein, we describe a rare TAVI-in-TAVI procedure with a self-expandable Medtronic Evolut R valve into a degenerated Medtronic CoreValve (Medtronic Medical Devices, Minneapolis, MN, USA) using 3D printing assistance and Claret Sentinel dual carotid filter for cerebral protection. Our aim is to highlight the importance of pre-TAVI imaging assessment in so complicated cases, like demanding ViV procedures.

Timeline

| Event                                | Timeframe (days) |
|--------------------------------------|-----------------|
| Eight years prior to presentation   |                 |
| Three months prior to presentation  | Transcatheter aortic valve implantation (TAVI) due to severe aortic stenosis. | Transcatheter aortic valve implantation (TAVI) due to severe aortic stenosis. |
| Upon presentation to the Catheterization Laboratory | Dyspnoea on effort [New York Heart Association (NYHA) Class III] and easy fatigue. The screening echocardiography documented severe aortic stenosis. Multimodality imaging assessment with computed tomography and three-dimensional printed model. | Successful TAVI in TAVI after post-dilation with fluoroscopic and echocardiographic guidance. |
| After 6 days                         | Discharge from hospital. | Discharge from hospital. |
| After 30 days                        | The first month echocardiography confirmed the proper valve-in-valve function, with significant clinical improvement (NYHA I–II). | The first month echocardiography confirmed the proper valve-in-valve function, with significant clinical improvement (NYHA I–II). |

Case presentation

A frail 78-year-old woman with a malfunctioning Medtronic Core Valve 26 mm, implanted in 2011 via TAVI technique due to severe aortic stenosis, was admitted to our outpatient cardiology clinic due to worsening dyspnoea on effort [New York Heart Association (NYHA) Class III] and easy fatigue, despite the optimal medical therapy. The physical exam revealed a harsh crescendo-descrescendo systolic murmur at the right upper sternal border with radiation to the carotid arteries, blood pressure 119/71 mmHg, heart rate 70 b.p.m., oxygen saturation on room air 93%, respiratory rate 18/min, mildly elevated jugular vein pressure, bilateral basal crackles, and mild peripheral oedema. The screening echocardiography documented severe aortic stenosis with aortic valve area 0.75 cm², mean transaortic gradient 40 mmHg and max transaortic gradient 61 mmHg, preserved left ventricular function and right ventricular systolic pressure 60 mmHg, while the coronary angiography ruled out any significant coronary disease. Arterial hypertension, dyslipidaemia, pulmonary hypertension, and paroxysmal atrial fibrillation under anticoagulation were the main comorbidities, while a permanent pacemaker implantation was performed in 2011 post-TAVI due to complete heart block. Surgical risk scores were in favour of repeated TAVI (EuroSCORE II 5.67%), so the Heart Team of our hospital favoured percutaneous aortic ViV implantation over SAVR as the optimal strategy.

Based on computed tomography measurements (Figure 1), a 3D model was printed as a physical replica of patient’s unique anatomy, offering the chance to have the final implantation of the selected 26 mm self-expandable Evolut R valve visualized preoperatively (Figure 2). The rationale comes from the need to understand simultaneously multiple elements of the complex aortic root anatomy (the shape and dimensions of the aortic annulus, sinuses of Valsalva and sinotubular junction; the relationship of the coronary artery ostia relative to these structures; the distribution of calcifications on the aortic leaflets, the left ventricular outflow tract, and the ascending aorta) while a new transcatheter valve has to be implanted into a degenerated one. The use of cerebral protection device was also considered as a necessary part of the procedure, to avoid the spread of calcified debris or thrombi, from both the native valve and the TAVI valve, to the systemic circulation.

After informed consent was signed, the patient was transferred to the Catheterization Laboratory under general anaesthesia. While intravenous heparin infusion was used to achieve an activated clotting time of >200 s, a catheter Pigtail 6 F was placed to the aortic root for intervention guidance. At the same time, the Claret Sentinel device was placed from the anonymous artery to the left carotid artery via the right radial artery. Then, the...
bioprosthesis was carefully advanced through the stiff Confida wire via the left femoral artery and was deployed progressively in line with the visible margin of the previously optimally implanted CoreValve (Figure 3). Haemodynamic and echocardiographic measurements ruled out any significant valvular regurgitation after the implantation, but underlined the need for post dilatation with Z-med balloon due to high remaining transvalvular gradient. When the optimal haemodynamic result was achieved (Figure 4), the whole delivery system was removed and the left femoral artery was sutured with two Proglide percutaneous closure systems, while the findings from the Sentinel device proved to be aortic calcified debris. The patient was successfully weaned from the mechanical ventilation in the Catheterization Laboratory and was transferred to the Coronary Care Unit for further supervision. The echocardiography at discharge showed max aortic velocity 1.1 m/s and absence of significant paravalvular regurgitation, while the first month echocardiography confirmed the proper ViV function, with mean transvalvular gradient 2.6 mmHg across the valve (Figure 5). A significant clinical improvement (NYHA I–II) was also reported.

**Discussion**

The long-term durability of TAVI bioprosthetic valves remains a hot topic since its first introduction in 2002. Since the first published case
of TAVI-in-TAVI, a series of cases have been reported and several issues regarding proper terminology (‘valve-in-valve’, ‘Russian doll concept’, or ‘TAVI-in-TAVI’) appeared in the literature. On the other hand, the major periprocedural complications regarding this clinical scenario have been analysed such as bioprosthesis malpositioning, critical coronary flow obstruction and high post-operative transaortic gradients. Moreover, a possible valve underexpansion may affect the final leaflet configuration and function; consequently, the expected device durability may decline.

The procedural success is greatly dependent on a multimodality pre-TAVI imaging assessment with computed tomography, transoesophageal echocardiogram, and 3D printing modelling, offering valuable tools for the optimal sizing of the transcatheter valve and the reduction of any significant paravalvular leak. Especially, the anatomic dimensions of the pre-existing bioprosthesis, derived from accurate computed tomography measurements, are of high importance for the appropriate TAVI valve selection and the procedural success.

**Conclusions**

Despite the limited experience with 3D models in TAVI, it is crucial to broaden the use of tissue-mimicking phantoms as an important educational tool for physicians and trainees involved in the case. A visualized implantation model before the procedure may enhance communication with the patient and predict any procedural complications. Techniques such as material engineering, computer-assisted design and 3D printing technology are expected to meet the advances in diagnostic imaging, creating new solutions for both preprocedural assessment and treatment. It is obvious that the ViV evolution depicts a changing environment where the clinical needs not only to expand the limits of the modern technology but actively interact with the future.

**Lead author biography**

Vassileios Voudris, MD, PhD, FESC, FACC, is a Consultant Cardiologist, Clinical Director of Cardiology Department, Onassis Cardiac Surgery Center.

**Supplementary material**

Supplementary material is available at *European Heart Journal - Case Reports* online.
Acknowledgements
The authors would like to express particular gratitude to 3D LIFE S.A. (Athens, Greece) that supported trial pilot application recruitment of 3D printing usage as a pre-interventional tool as well as for training and educational purposes.

Funding
The authors would like to express particular gratitude to Onassis Cardiac Surgery Center for funding.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

Consent: The author/s confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidance.

Conflict of interest: none declared.

References
1. Kanakakis I. Is TAVR going to be our default choice for treating aortic valve stenosis? Hellenic J Cardiol 2019; 60:146–147.
2. Eftychiou C, Kokkinos C, Evangelakis E, Houri S, Simamonian K, Yiannikourides V et al. Repeated transapical TAVI for the treatment of a degenerated bioprosthetic valve. Hellenic J Cardiol 2018; 59:40–42.
3. Petronio AS, Giannini C. Developments in transcatheter aortic bioprosthesis durability. Expert Rev Cardiovasc Ther 2019; 17:857–862.
4. Valvo R, Criscione E, Reddavid C, Barbanti M. Early detection of transcatheter heart valve dysfunction. Expert Rev Cardiovasc Ther 2019; 17:863–872.
5. Vrachatis DA, Vavuranakis M, Tsoukala S, Sotiria G, Papaioannou TG, Siasos G et al. “TAVI: Valve in Valve. A new field for structuralists? Literature review”. Hellenic J Cardiol 2019; 51:9966(19):30294-5.
6. Buzzatti N, Romano V, De Backer O, Soendergaard L, Rosseel L, Maurovich-Horvat P et al. Coronary access after repeated transcatheter aortic valve implantation: a glimpse into the future. JACC Cardiovasc Imaging 2020; 13: 508–515.
7. Bompotis G, Meletidou M, Karakanas A, Sotiriou S, Sachpekis V, Konstantinidou M et al. Transcatheter aortic valve implantation using 3-D printing modeling assistance. A single-center experience. Hellenic J Cardiol 2019; 51:9666(18):30596-7.
8. Koo HJ, Choe J, Kang DY, Ko E, Ahn JM, Park DW et al. Computed tomography features of cuspal thrombosis and subvalvular tissue ingrowth after transcatheter aortic valve implantation. *Am J Cardiol* 2019;125:597–606.

9. Seeger J, Kapadia SR, Kodali S, Linke A, Wöhrlé J, Haussig S et al. Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis. *Eur Heart J* 2019;40:1334–1340.

10. Latsios G, Spyridopoulos TN, Toutouzas K, Synetos A, Trantas G, Stathogiannis K et al. Multi-slice CT (MSCT) imaging in pretrans-catheter aortic valve implantation (TAVI) screening. How to perform and how to interpret. *Hellenic J Cardiol* 2018;59:3–7.

**Figure 5** First month follow-up echocardiography.